LBA44Overall survival at 4 years of follow-up in a phase III trial of nivolumab plus ipilimumab combination therapy in advanced melanoma (CheckMate 067). (23rd October 2018) - Hodi, F S; Chiarion-Sileni, V; Gonzalez, R; Grob, J J; Rutkowski, P; Cowey, C L; Lao, C; Schadendorf, D; Wagstaff, J; Dummer, R; Ferrucci, P F; Smylie, M; et al.